← Back to Search

Monoclonal Antibodies

LY3462817 for Rheumatoid Arthritis

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights

Study Summary

This study is evaluating whether a drug may help reduce symptoms of rheumatoid arthritis.

Eligible Conditions
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP)
Secondary outcome measures
Change From Baseline for Mean Clinical Disease Activity Index (CDAI)
Change From Baseline for Mean Simplified Disease Activity Index (SDAI)
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
+4 more

Side effects data

From 2022 Phase 2 trial • 98 Patients • NCT04634253
8%
Nasopharyngitis
4%
Dizziness
4%
Sinusitis
4%
Gastroenteritis
4%
Covid-19
4%
Skin bacterial infection
4%
Weight increased
4%
Helicobacter infection
4%
Mastitis
4%
Allodynia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
LY3462817 300 mg
LY3462817 700 mg

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3462817 700 mgExperimental Treatment1 Intervention
Participants received IV infusion of 700 mg LY3462817 solution.
Group II: LY3462817 300 mgExperimental Treatment1 Intervention
Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
Group III: PlaceboPlacebo Group1 Intervention
Participants received IV infusion of 0.9% sodium chloride solution (Placebo).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3462817
2021
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,618 Previous Clinical Trials
3,201,419 Total Patients Enrolled
28 Trials studying Rheumatoid Arthritis
17,080 Patients Enrolled for Rheumatoid Arthritis
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,613 Total Patients Enrolled
17 Trials studying Rheumatoid Arthritis
13,445 Patients Enrolled for Rheumatoid Arthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of LY3462817 in Participants With Rheumatoid Arthritis
2021. "A Study of LY3462817 in Participants With Rheumatoid Arthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04634253.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top